James Edgemond Sells 9,636 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 9,636 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $572.21, for a total transaction of $5,513,815.56. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,801,035.96. This trade represents a 33.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The shares were sold at an average price of $575.85, for a total transaction of $209,609.40.
• On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.86, for a total transaction of $5,778,600.00.
• On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.18, for a total transaction of $5,771,800.00.
• On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.88, for a total transaction of $5,748,800.00.
• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.89, for a total transaction of $5,778,900.00.
• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total transaction of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total transaction of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $535.90, for a total transaction of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00.

United Therapeutics Stock Performance

United Therapeutics stock traded down $5.69 during mid-day trading on Friday, hitting $567.16. 264,756 shares of the company traded hands, compared to its average volume of 491,071. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $607.89. The stock has a market cap of $24.86 billion, a price-to-earnings ratio of 20.33, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75. The stock has a fifty day moving average price of $534.64 and a 200-day moving average price of $493.24.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period in the previous year, the business posted $6.19 earnings per share. United Therapeutics’s revenue for the quarter was up 7.4% on a year-over-year basis. Sell-side analysts predict that United Therapeutics Corporation will post 27.97 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Torren Management LLC purchased a new position in shares of United Therapeutics during the fourth quarter worth approximately $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics in the fourth quarter worth $31,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

UTHR has been the subject of several research analyst reports. UBS Group lifted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Bank of America lifted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Morgan Stanley lifted their price target on shares of United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Ten analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $601.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.